Membrane glycoproteins (GP) IIb and IIIa are not detectable on the platelets of a majority (Type 1) of patients with Glanzmann’s thrombasthenia, a hereditary disorder of platelet function characterized by an absence of platelet-platelet adhesion. These platelets also do not express the human platelet alloantigen, PlA1, a finding which led to the demonstration that the PlA1 alloantigen is associated with GPIIIa, but not with GPIIb. Alloantibodies directed against the PlA1 determinant or certain other determinants associated with GPIIb and/or GPIIIa appear to be capable of inhibiting normal platelet- platelet adhesion, suggesting that these glycoproteins function as key mediators of this process, an obligate step in normal hemostasis. Subsequent studies have supported this hypothesis by demonstrating that fibrinogen, which is known to be a key cofactor in normal platelet aggregation, does not bind to thrombasthenic platelets.We have used crossed immunoelectrophoresis of Triton X-100 soluble membrane glycoproteins against a multispecific rabbit antibody to quantitate levels of GPIIb and GPIIIa on normal and thrombasthenic platelets and to study the interaction of these two glycoproteins in a soluble nondenatured state. These studies have provided information on 1) the inheritance of PlA1 and the glycoprotein IIb/IIIa defect in Glanzmann’s thrombasthenia, and 2) reversible Ca++-dependent changes in the orientation of GPIIb and GPIIIa, which may contribute to understanding of the function of these glycoproteins in normal platelet aggregation. In the presence of sufficient Ca++, glycoproteins IIb and IIIa were found to exist only in heterogenous complexes, whether within isolated membranes, or in solution. Chelation of Ca++ by EDTA or EGTA resulted in the dissociation of these glycoproteins; reassociation could be induced by readdition of excess Ca++.